About this trial
Type I interferonopathies are rare autoinflammatory disorders caused by genetic defects and associated with significant morbidity and mortality. These diseases are refractory to conventional immunosuppressive therapies. They typically occur in childhood, although disease onset in adulthood has been observed. The clinical spectrum is wide and mainly involves the central nervous system. Joint involvement is also common, and more rarely, haematological features such as cytopenias or immunodeficiency may be observed.
Nearly all patients show consistent over-activation of the type I IFN pathway, as evidenced, the expression of IFN-stimulated genes, the so-called 'interferon signature'. To date, the natural history of interferonopathies remains unclear.
In this context, the establishment of a natural history of type I interferonopathy in patients is proposed to elucidate the pathophysiological mechanisms and identify biomarkers for diagnosis, prognosis, and disease activity, with the aim of better characterising the diversity of interferonopathies.
The main objective is to characterise the evolution of the pathology in paediatric and adult patients with type I interferonopathies.
The overall aim of this research is to propose therapeutic options tailored to patient phenotypes and to better define patient sub-groups in order to optimise the preparation of future clinical trials.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Genetically confirmed patient with type I interferonopathy
Patient affiliated to a social security scheme or beneficiary of such a scheme.
Disqualifiers
None
Trial population
Patients with genetically confirmed type I interferonopathy in Europe. 500 patients estimated.
Trial design
Cohort
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Characterizing disease progression in pediatric and adult patients with type I interferonopathies
Composite description of phenotypes of patients with type I interferonopathies according to genotype (clinical, biological) over time.
Secondary outcomes
Identifing and characterising genotype-specific immunological factors
Description of specific immunological factors according to genotype
Research of biomarkers for diagnosis, prognosis and monitoring of disease activity
Biomarkers identified for diagnosis, prognosis and monitoring of disease activity
Monitoring of treatment response according to phenotype and genotype
Treatment response by phenotype and genotype
Sponsors and contacts
Click on the lead sponsor to view all of their trials.